For Patients
Working to Delay the Onset and Progression of Type 1 Diabetes
An estimated 8.4 million people were living with type 1 diabetes (T1D) around the globe in 2021, and this number is predicted to increase to 13.5-17.4 million by 2040. With diagnoses on the rise, and the significant daily burden on patients and their caregivers/families to manage T1D symptoms and potential complications, there is an urgent need for treatment options that can target the underlying cause of disease and potentially modify its progression without significant side effects.
That’s why we’re focused on developing SAB-142 to delay onset and potentially prevent the progression of T1D in adults with Stage 3 T1D. SAB-142 is not another insulin nor is it for chronic disease management, it is a potentially disease-modifying therapy for T1D over a patient’s lifespan.
A list of SAB BIO open clinical trials can be found here: https://clinicaltrials.gov/
More information about our Expanded Access Policy is available here: https://www.sab.bio/expanded-access-policy/.
For more information and resources about T1D, we encourage you to visit: